Charlotte E Mills1,2,3, Virginia Govoni1,2, Luca Faconti2,4, Maria-Linda Casagrande1,2, Steven V Morant5, Hannah Crickmore1, Fahad Iqbal1, Perry Maskell5, Alisha Masani5, Elisa Nanino1,2, Andrew J Webb2,4, J Kennedy Cruickshank1,2. 1. Cardiovascular Medicine Group, Department of Nutritional Sciences, School of Life Course Sciences, King's College London, UK. 2. Biomedical Research Centre, Clinical Research Facility, 4th Floor, North Wing, St Thomas' Hospital, Guy's and St Thomas' NHS Foundation Trust, London, UK. 3. Hugh Sinclair Unit of Human Nutrition, Department of Food and Nutritional Sciences, University of Reading, UK. 4. King's College London British Heart Foundation Centre, School of Cardiovascular Medicine and Sciences, Department of Clinical Pharmacology, UK. 5. Medicines Monitoring Unit (MEMO), University of Dundee, UK.
Abstract
AIMS: To test if spironolactone or dietary nitrate from beetroot juice could reduce arterial stiffness as aortic pulse wave velocity (PWVart), a potential treatment target, independently of blood pressure. METHODS:Daily spironolactone (≤50 mg) vs doxazosin (control ≤16 mg) and 70 mL beetroot juice (Beet-It ≤11 mmol nitrate) vs nitrate-depleted juice (placebo; 0 mmol nitrate) were tested in people at risk or with type-2 diabetes using a double-blind, 6-month factorial trial. Vascular indices (baseline, 12, 24 weeks) were cardiac-ankle vascular index (CAVI), a nominally pressure-independent stiffness measure (primary outcome), PWVart secondary, central systolic pressure and augmentation. Analysis was intention-to-treat, adjusted for systolic pressure differences between trial arms. RESULTS: Spironolactone did not reduce stiffness, with evidence for reduced CAVI on doxazosin rather than spironolactone (mean difference [95% confidence interval]; 0.25 [-0.3, 0.5] units, P = .080), firmer for PWVart (0.37 [0.01, 0.7] m/s, P = .045). There was no difference in systolic pressure reduction between spironolactone and doxazosin (0.7 [-4.8, 3.3] mmHg, P = .7). Circulating nitrate and nitrite increased on active vs placebo juice, with central systolic pressure lowered -2.6 [-4.5, - 0.8] mmHg, P = .007 more on the active juice, but did not reduce CAVI, PWVart or peripheral pressure. Change in nitrate and nitrite concentrations were 1.5-fold [1.1-2.2] and 2.2-fold [1.3, 3.6] higher on spironolactone than on doxazosin respectively; both P < .05. CONCLUSION: Contrary to our hypothesis, in at-risk/type 2 diabetes patients, spironolactone did not reduce arterial stiffness, rather PWVart was lower on doxazosin. Dietary nitrate elevated plasma nitrite, selectively lowering central systolic pressure, observed previously for nitrite.
RCT Entities:
AIMS: To test if spironolactone or dietary nitrate from beetroot juice could reduce arterial stiffness as aortic pulse wave velocity (PWVart), a potential treatment target, independently of blood pressure. METHODS: Daily spironolactone (≤50 mg) vs doxazosin (control ≤16 mg) and 70 mL beetroot juice (Beet-It ≤11 mmol nitrate) vs nitrate-depleted juice (placebo; 0 mmol nitrate) were tested in people at risk or with type-2 diabetes using a double-blind, 6-month factorial trial. Vascular indices (baseline, 12, 24 weeks) were cardiac-ankle vascular index (CAVI), a nominally pressure-independent stiffness measure (primary outcome), PWVart secondary, central systolic pressure and augmentation. Analysis was intention-to-treat, adjusted for systolic pressure differences between trial arms. RESULTS:Spironolactone did not reduce stiffness, with evidence for reduced CAVI on doxazosin rather than spironolactone (mean difference [95% confidence interval]; 0.25 [-0.3, 0.5] units, P = .080), firmer for PWVart (0.37 [0.01, 0.7] m/s, P = .045). There was no difference in systolic pressure reduction between spironolactone and doxazosin (0.7 [-4.8, 3.3] mmHg, P = .7). Circulating nitrate and nitrite increased on active vs placebo juice, with central systolic pressure lowered -2.6 [-4.5, - 0.8] mmHg, P = .007 more on the active juice, but did not reduce CAVI, PWVart or peripheral pressure. Change in nitrate and nitrite concentrations were 1.5-fold [1.1-2.2] and 2.2-fold [1.3, 3.6] higher on spironolactone than on doxazosin respectively; both P < .05. CONCLUSION: Contrary to our hypothesis, in at-risk/type 2 diabetespatients, spironolactone did not reduce arterial stiffness, rather PWVart was lower on doxazosin. Dietary nitrate elevated plasma nitrite, selectively lowering central systolic pressure, observed previously for nitrite.
Authors: Elizabeth Selvin; Michael W Steffes; Hong Zhu; Kunihiro Matsushita; Lynne Wagenknecht; James Pankow; Josef Coresh; Frederick L Brancati Journal: N Engl J Med Date: 2010-03-04 Impact factor: 91.245
Authors: Kennedy Cruickshank; Lisa Riste; Simon G Anderson; John S Wright; Graham Dunn; Ray G Gosling Journal: Circulation Date: 2002-10-15 Impact factor: 29.690
Authors: Enrico Vizzardi; Paolo Della Pina; Giorgio Caretta; Ivano Bonadei; Edoardo Sciatti; Carlo Lombardi; Antonio D'Aloia; Antonio Curnis; Marco Metra Journal: J Cardiovasc Med (Hagerstown) Date: 2015-09 Impact factor: 2.160
Authors: Barry R Davis; John B Kostis; Lara M Simpson; Henry R Black; William C Cushman; Paula T Einhorn; Michael A Farber; Charles E Ford; Daniel Levy; Barry M Massie; Shah Nawaz Journal: Circulation Date: 2008-11-10 Impact factor: 29.690
Authors: Charlotte Elizabeth Mills; Jibran Khatri; Perry Maskell; Chimed Odongerel; Andrew James Webb Journal: Br J Clin Pharmacol Date: 2016-05-06 Impact factor: 4.335
Authors: Joshua M Bock; William E Hughes; Kenichi Ueda; Andrew J Feider; Satoshi Hanada; Darren P Casey Journal: Am J Hypertens Date: 2022-09-01 Impact factor: 3.080
Authors: Oliver M Shannon; Chris Easton; Anthony I Shepherd; Mario Siervo; Stephen J Bailey; Tom Clifford Journal: BMC Sports Sci Med Rehabil Date: 2021-06-07